[1] Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference statement:management of hepatitis B. Hepatology,2009,49:S4-S12.
[2] Wieland S, Thimme R, Purcell RH, et al. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A,2004,101:6669-6674.
[3] Ramboer E, Craene BD, Kock JD, et al. Strategies for immortalization of primary hepatocytes. J Hepatol,2014,61:925-943.
[4] Mabit H, Vons C, Dubanchet S, et al. Primary cultured normal human hepatocytes for hepatitis B virus receptor studies. J Hepatol,1996,24: 403-412.
[5] Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos,2003,31:1035-1042.
[6] Lin M, Chen Q, Yang LY, et al. Hepatitis B virus infection and replication in primarily cultured human fetal hepatocytes. World J Gastroenterol,2007,13:1027-1031.
[7] Zhou M, Zhao F, Li J, et al. Long-term maintenance of human fetal hepatocytes and prolonged susceptibility to HBV infection by co-culture with non-parenchymal cells. J Virol Methods,2014,195:185-193.
[8] Zhou M, Huang YY, Cheng ZK, et al. Revival, charact-erization, and hepatitis B virus infection of cryopreserved human fetal hepatocytes. J Virol Methods,2014,207:29-37.
[9] Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA,2002,99:15655-15660.
[10] Aninat C, Piton A,Glaise D,et al.Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos,2006,34:75-83.
[11] Leonard J, Nelson, Katie M, et al. Human hepatic hepaRG cells maintain an organotypic phenotype with high intrinsic CYP450 activity/metabolism and significantly outperform standard Hep G2/C3A cells for pharmaceutical and therapeutic applications. Basic Clin Pharmacol Toxicol,2017,120:30-37.
[12] Hantz O, Parent R, Durantel D, et al. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol,2009,90:127-135.
[13] Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science,1980,209:497-499.
[14] Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother,1997,41:1715-1720.
[15] Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA,1987,84:1005-1009.
[16] Acs G, Sells MA, Purcell RH, et al. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci USA,1987,84:4641-4644.
[17] Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother,1997,41:1715-1720.
[18] Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol,2009,51:581-592.
[19] Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother,2012,56:4277-4288.
[20] Guo H, Jiang D, Zhou T, et al. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol,2007,81:12472-12484.
[21] Cai D, Wang X, Ran Y, et al. Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. J Antiviral,2016,132:26-37.
[22] Jiang Y, Wang AH, Shao LH, et al. A new cell culture system for infection with hepatitis B virus that fuses Hep G2 cells with primary human hepatocytes. J Int Med Res,2009,37:650-661.
[23] Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.Drug Transporters. Handb Exp Pharmacol,2011,201:205-259.
[24] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife,2012,3:e00049-e00049.
[25] Schulze A, Mills K, Weiss TS, et al. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology,2012,55:373-383.
[26] Yan H, Liu Y, Sui J, et al. NTCP opens the door for hepatitis B virus infection. Antivir Res,2015,121:24-30.
[27] Hayes CN, Chayama K. HBV culture and infectious systems. Hepatol Int,2016,10:559-566.
[28] Verrier ER, Che CC, Schuster C, et al. Cell culture models for the investigation of hepatitis B and D virus infection. Viruses,2016,8: 261.
[29] Li W. The hepatitis B virus receptor. Annu Rev Cell Dev Biol,2015, 31:125-147.
[30] Watashi K, Urban S, Li W, et al. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci,2014,15:2892-2905.
[31] Yan R, Zhang Y, Cai D, et al. Spinoculation enhances HBV infection in NTCP-reconstituted hepatocytes. PLoS One,2015,10:e0129889.
[32] Okuyamadobashi K, Kasai H, Tanaka T, et al. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci Rep,2015,5:17047.
[33] Hayes CN, Chayama K. HBV culture and infectious systems. Hepa Inter, 2016,10:559-566.
[34] Li J, Zong L, Sureau C, et al. Unusual features of sodium taurocholate cotransporting polypeptide as a hepatitis B virus receptor. J Virol,2016,90:8302-8313. |
